KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
Executive Summary
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
You may also be interested in...
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Morphine sulfate extended-release product’s approval with only one of three routes of abuse raises questions about how effectively US FDA’s policies are encouraging development of abuse-deterrent opioid formulations.
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
Company cites FDA 'confusion' and indicates it will drop the product without the claim.
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.